Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Ottawa, April 08, 2025 (GLOBE NEWSWIRE) -- The global chronic obstructive pulmonary disease market size was valued at USD 22.55 billion in 2024 and is predicted to hit around USD 33.29 billion by ...

Inpatient pulmonary rehabilitation significantly enhances functional independence in patients with chronic lung disease and ...

Climate change is affecting the health of all individuals and represents an even more significant health risk for individuals with COPD.

A new study from University Hospitals Connor Whole Health found that it was feasible to conduct a hybrid music therapy ...

Pulmonologists share best practices on when primary care providers should consider sending patients with respiratory ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

Vaping may seem safer than smoking cigarettes, but it won’t protect you from lung damage.